GlassScriptPhysician profile
Houssam Mhanna
NPI 1508105560
$5,395.86
in general payments reported to CMS, 2019-2025
24 companies · $1,148 in 2025
The $1,148 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $14.37 · 2021: $183 · 2022: $1,051 · 2023: $1,208 · 2024: $1,598 · 2025: $1,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,780 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,780.00 |
| Education | $174.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $867.93 | 2020-2023 | Krystexxa |
| Astrazeneca Pharmaceuticals LP | $647.35 | 2022-2025 | Lokelma, Farxiga, Brilinta |
| Otsuka America Pharmaceutical, INC. | $598.29 | 2021-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $487.62 | 2022-2025 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $376.06 | 2022-2025 | |
| Ardelyx, INC. | $342.38 | 2024-2025 | Ibsrela, Xphozah 30 Mg |
| Fresenius USA Marketing, INC. | $340.85 | 2019-2025 | Velphoro, Velphoro |
| Novo Nordisk INC | $306.47 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Mallinckrodt Hospital Products INC. | $261.89 | 2022-2025 | Acthar |
| Amgen INC. | $211.67 | 2024-2025 | Krystexxa |
| Corcept Therapeutics | $141.49 | 2024-2025 | Korlym |
| Alexion Pharmaceuticals, INC. | $136.18 | 2022-2025 | Soliris, Ultomiris |
| Boehringer Ingelheim Pharmaceuticals, INC. | $129.32 | 2023-2025 | Jardiance |
| Vifor Pharma, INC. | $94.58 | 2022-2023 | Korsuva, Veltassa |
| Novartis Pharmaceuticals Corporation | $81.68 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $79.32 | 2023-2025 | Purified Cortrophin Gel |
| Travere Therapeutics, INC. | $61.46 | 2022-2023 | |
| Scpharmaceuticals INC. | $59.28 | 2024-2025 | |
| Lilly USA, LLC | $51.31 | 2023-2025 | Jardiance, Zepbound, Mounjaro |
| Akebia Therapeutics INC | $48.87 | 2024 | Vafseo, Auryxia |
| Nxstage Medical, INC. | $20.87 | 2024 | |
| Genzyme Corporation | $20.50 | 2023 | |
| Glaxosmithkline, LLC. | $16.87 | 2023 | Benlysta |
| Daiichi Sankyo INC. | $13.62 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Houssam Mhanna listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.